Prof. Frankel (London, UK)

For me, CARMELINA and CAROLINA provide evidence for cardiovascular and kidney safety profile of Trajenta across a broad range of people with type 2 diabetes. This, when combined with Trajenta’s proven efficacy and unique convenience of always one dose, once daily, reinforces the simplicity of Trajenta in managing patients with type 2 diabetes. In practice, when considering an up-titration of treatment where a DPP4 inhibitor is a potential option, it is important to have an informed discussion with the person with diabetes so that they understand what the different options mean in relation to both effectiveness and potential adverse events.